MedPath

BYOOVIZ

BYOOVIZ

Approved
DIN Number

02525852

Drug Class

Human

Market Date

Mar 1, 2023

Company
HC

Samsung Bioepis Co., Ltd.

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02525852
AIG Number0152224001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Schedule D ,  Prescription
A
ATC Code
S01LA04 RANIBIZUMAB
Product Specifications
Dosage FormSolution
Route of AdministrationIntravitreal
AHFS Classification52:92.00
Health Canada Classification

ACTIVE INGREDIENTS (1)

RANIBIZUMABActive
Strength: 10 MG / ML
Monograph: RANIBIZUMAB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.